Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00446
|
|||||
| Drug Name |
Repaglinide
|
|||||
| Synonyms |
(+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AG-EE-388; AG-EE-623 ZW; AGEE-623ZW; Actulin; Glaxo Wellcome brand of replaginide; GlucoNorm; GlucoNorm (TN); NN-623; Novo Nordisk brand 2 of repaglinide; Novo Nordisk brand of repaglinide; NovoNorm; NovoNorm (TN); Prandin; Prandin (TN); Prandin, GlucoNorm, NovoNorm, Repaglinide; Repa-glinide; Repaglinida; Repaglinida [INN-Spanish]; Repaglinide (JAN/USP/INN); Repaglinide [USAN]; Repaglinide, (+-)-isomer; Repaglinidum; Repaglinidum [INN-Latin]; SMP-508
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11:5A11] | Approved | [1] | |||
| Therapeutic Class |
Hypoglycemic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H36N2O4
|
|||||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
|
|||||
| InChI |
InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
|
|||||
| InChIKey |
FAEKWTJYAYMJKF-QHCPKHFHSA-N
|
|||||
| CAS Number |
CAS 135062-02-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 452.6 | Topological Polar Surface Area | 78.9 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
5.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103394824
,103914669
,104041348
,104179029
,104335174
,11112894
,11467074
,11468194
,11486642
,117545849
,117873275
,12014667
,121363609
,124659000
,124757239
,124799919
,125164043
,14808699
,14833410
,24724596
,26719812
,43122707
,46386564
,46508150
,47425572
,48244693
,48319772
,48395177
,48416511
,49648522
,49699266
,49888451
,50100536
,52108264
,53789672
,57315871
,7847660
,7980507
,81092844
,8190080
,85788088
,92125938
,92308165
,92308498
,92719265
,93166496
,9872
,99218180
,99431925
,99437146
|
|||||
| ChEBI ID |
CHEBI:8805
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
| References | ||||||
| 1 | Repaglinide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.